[HTML][HTML] Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer

R Leão, JD Apolónio, D Lee, A Figueiredo… - Journal of biomedical …, 2018 - Springer
Background Limitless self-renewal is one of the hallmarks of cancer and is attained by
telomere maintenance, essentially through telomerase (h TERT) activation. Transcriptional …

[HTML][HTML] Papillary thyroid cancer prognosis: An evolving field

S Ulisse, E Baldini, A Lauro, D Pironi, D Tripodi, E Lori… - Cancers, 2021 - mdpi.com
Simple Summary Over the last couple of decades, the prognostic stratification systems of
differentiated thyroid cancer (DTC) patients have been revised several times in an attempt to …

Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology: a prospective blinded multicenter study

DL Steward, SE Carty, RS Sippel, SP Yang… - JAMA …, 2019 - jamanetwork.com
Importance Approximately 20% of fine-needle aspirations (FNA) of thyroid nodules have
indeterminate cytology, most frequently Bethesda category III or IV. Diagnostic surgeries can …

[HTML][HTML] Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to …

JM Oh, BC Ahn - Theranostics, 2021 - ncbi.nlm.nih.gov
The advanced, metastatic differentiated thyroid cancers (DTCs) have a poor prognosis
mainly owing to radioactive iodine (RAI) refractoriness caused by decreased expression of …

[HTML][HTML] Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer

SK Yoo, YS Song, EK Lee, J Hwang, HH Kim… - Nature …, 2019 - nature.com
Anaplastic thyroid cancer (ATC) and advanced differentiated thyroid cancers (DTCs) show
fatal outcomes, unlike DTCs. Here, we demonstrate mutational landscape of 27 ATCs and …

[HTML][HTML] Novel targeted therapies and immunotherapy for advanced thyroid cancers

GE Naoum, M Morkos, B Kim… - Molecular …, 2018 - molecular-cancer.biomedcentral …
Thyroid cancer is a frequently encountered endocrine malignancy. Despite the favorable
prognosis of this disease, 15–20% of differentiated thyroid cancer (DTC) cases and most …

Molecular targets of tyrosine kinase inhibitors in thyroid cancer

P Fallahi, SM Ferrari, MR Galdiero, G Varricchi… - Seminars in Cancer …, 2022 - Elsevier
Thyroid cancer (TC) is the eighth most frequently diagnosed cancer worldwide with a rising
incidence in the past 20 years. Surgery is the primary strategy of therapy for patients with …

Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in …

R Liu, J Bishop, G Zhu, T Zhang, PW Ladenson… - JAMA …, 2017 - jamanetwork.com
Importance BRAF V600E andTERTpromoter mutations can coexist in papillary thyroid
cancer (PTC). This genetic duet was indicated to be involved in the aggressiveness of PTC …

[HTML][HTML] Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer

R Liu, T Zhang, G Zhu, M Xing - Nature communications, 2018 - nature.com
The unique oncogene duet of coexisting BRAF V600E and TERT promoter mutations are
widely found to be a robust genetic background promoting human cancer aggressiveness …

Multiplatform molecular test performance in indeterminate thyroid nodules

MA Lupo, AE Walts, JW Sistrunk… - Diagnostic …, 2020 - Wiley Online Library
Background Approximately 25% of thyroid nodule fine‐needle aspirates (FNAs) have
cytology that is indeterminate for malignant disease. Accurate risk stratification of these …